Depression dose study pulled before starting

NCT ID NCT05210153

Terminated Knowledge-focused Sponsor: University of Belgrade Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to see if measuring sertraline (Zoloft) levels in the blood and checking a specific gene (CYP2C19) could help doctors give the right dose to people with major depression. The goal was to reduce side effects and improve treatment. However, the study was withdrawn before enrolling any participants, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sertraline (Zoloft)

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEPRESSIVE DISORDER, MAJOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DEPRESSIVE DISORDER, MAJOR

Contacts and locations

Locations

Clinical Centre of Serbia

Belgrade, 11000, Serbia
Institute of Mental Health

Belgrade, 11000, Serbia
Military Medical Academy

Belgrade, 11000, Serbia

More trials for these conditions

Other studies related to the condition(s) this trial covers.